Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab
- Development stage
- Approved
- Lead developer
- AstraZeneca
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Durvalumab is a fully human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and immune checkpoint inhibitor developed for the treatment of various cancers. It works by selectively binding to programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 receptors on T cells. This blockade prevents tumor cells from evading immune surveillance, thereby enhancing T-cell-mediated recognition and killing of cancer cells. Durvalumab is indicated for non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), unresectable hepatocellular carcinoma (HCC), advanced or recurrent mismatch repair deficient endometrial cancer, and muscle invasive bladder cancer in certain patients. The drug is administered intravenously as an infusion every 2 to 4 weeks depending on indication[1][3][6][7].
- Brand names
- Imfinzi
- Other names
- durvalumabMEDI4736MEDI-4736MEDI 4736Imfinzi
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on durvalumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab.